SENSIMED Triggerfish

60 subjects will be enrolled in total. Enrolled patients will be randomized into one of 8 device groups of 6 subjects each or into the control group containing 12 subjects. Patients in the device arm will receive one session of 3-to 24-hour continuous IOP monitoring with SENSIMED Triggerfish®. SENSIMED Triggerfish® monitoring will begin at 18h ± 2 hours for all patients. SENSIMED Triggerfish® will be installed randomly on right or left eyes. During SENSIMED Triggerfish® monitoring on one eye, GAT and/or Perkins IOP measurements will be taken in the fellow eye every 3 hours. Outside this time they will receive GAT and/or IOP measurements every 3 hours in both eyes until the end of the 24-hours period. Patients in the control group will receive GAT and/or ICare PRO IOP measurements every 3 hours for 24 hours in both eyes.

Inclusion criteria

• Signed informed consent for the investigation
• Confirmed diagnosis of primary open angle glaucoma or normal tension glaucoma of similar degree in both eyes
• Age 18-85
• Stable anti-glaucomatous therapy 4 weeks before and throughout the investigation

Exclusion criteria

• Patients not able to understand the character and individual consequences of the investigation
• Patients with contraindications for silicone contact lens wear
• Wear of full frame metallic glasses during SENSIMED Triggerfish® monitoring
• Diagnosis of pseudoexfoliation syndrome / pseudoexfoliative glaucoma and of pigment dispersion syndrome / pigmentary glaucoma
• Severe dry eye
• Patients who have had ocular surgery within the last 3 months
• Corneal or conjunctival abnormality or irregularity hindering correct contact lens adaptation
• Allergy to corneal anaesthesia
• Simultaneous participation in other clinical research